Evolus Inc (EOLS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $460.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Evolus Inc (EOLS) Stock Forecast
Analysts expect Evolus (EOLS) to earn -$0.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $334.27M. Of 6 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 4 | 66.7% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 16.9%.
- Fiscal year ending Dec 31, 2026
- -$0.07
- EPS consensus, revenue $334.27M
- Fiscal year ending Dec 31, 2027
- $0.28
- EPS consensus, revenue $390.61M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.07 to -$0.07 | 1 | $334.27M | $333.37M to $335.75M | 6 |
| Dec 31, 2027 | $0.28 | $0.21 to $0.38 | 3 | $390.61M | $372.80M to $406.47M | 6 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.06 | $0.00 to $0.15 | 8 | $101.12M | $96.24M to $105.61M | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 9 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.07 | -$0.05 | -$0.05 | -$0.04 | -$0.05 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.28 | $0.29 | $0.29 | $0.28 | $0.26 | +8.5% |
Frequently Asked Questions About EOLS
What is the EOLS stock forecast?
Consensus analyst estimates put Evolus's EPS at -$0.07 for the fiscal year ending Dec 31, 2026, on revenue of $334.27M. The consensus rating from 6 analysts is Buy.
How do analysts rate EOLS stock?
Of 6 analysts covering Evolus, 1 rates it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from EOLS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.07, with estimates from -$0.07 to -$0.07 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.28, with estimates from $0.21 to $0.38 from 3 analysts.
What revenue do analysts expect from Evolus next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $334.27M, with estimates from $333.37M to $335.75M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $390.61M, with estimates from $372.80M to $406.47M.
How many analysts cover EOLS?
6 analysts rate Evolus stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
EOLS pages: Overview, Earnings, Forecast, Financials, Competitors